Hepion Pharmaceuticals Inc (HEPA)

[Fress]

Be patient! Be patient!

That’s a big mental game boys, they create fear and doubt to scare us with the stock price. Nothing change in fact.

Keep your shares strong.
I had enough experience to told you many good news will come in the next weeks.

Let’s give a chance to Dr Foster to show us whats behind thousands and thousands hours of sacrefice/efforts In the lab.

Catalyst / News coming:

Phase 2A / 225 mg dose
Phase 2B starts 2021

Dr Hobbs join Hepion in Feb Vice President snd CMO of Novo Nordisk 190 billion dollar company.

Hobbs leaves a 183 Billion dollar company with the one the biggest pharmaceutical companies with a very cushy job and you can damn well bet that he didn't leave his VP/CMO position thto take lead CMO at HEPA think about it! He's not going to Hepa to play %$%& tiddlywinks
http://www.pharmafile.com/news/521552/working-life-dr-todd-hobbs-vice-president-and-chief-medical-officer-novo-nordisk

Dr Mayo SVP

AI POWR platform +

115 million in cash burning under 5 million a quarter.

150 million market cap.


85%~90% of shares being held by institutions and insiders after the 2 offerings strong cash position!

- Partnership / Mix CRV-431 with others pills / molecule
- News Positive effects of CRV-431
Hepa other possible indications:
Diabetes.
Hepatitis
HVB.
Alzheimer’s
NASH Nash drug CRV431( 500 Million patients in the world )
Covid.
Endometrial Carcinoma.

100x ROI potential from these levels by 2025


Hepa competitors' greatly inferior NASH drugs are being valued in the billions. Just a 1B MC for Hepion makes for $13.12 a share, and CRV431 is going to eventually treat many other indications, some with treatment markets in the many tens of billions

In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.


The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach $84 Billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029


Lastly there are 76 million HEPA shares outstanding. >95% institutional ownership.
No filings were submitted for ~70% of the 64m shares bought at the November and February offerings, meaning the vast majority was concealed.
Before institutions bought 64m shares at those offerings, there were 12m shares out, with 3m in the public float. So, direct holders had ~9m shares of that, and tutes got 64m at the offerings, which possibly left ~3m for retail then. Also the chart just reversed.

There are no shares available the MM are swapping spit with one another's accounts trying to pry loose a few shares from weak pathetic and uneducated retail types. HEPA stock can double or triple in a blink of an eye just have the vision and patience and balls of fortitude. Diamond hands laser eyed Hepa Bulls long & strong! This small biotech 160 million market cap has potential to reach tens of billions of dollars buy hold and forget about it and lock up your shares up.


Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 150 Million market cap 120 million in cash

$HEPA